Amsterdam, September 19, 2012 – Life Sciences Partners (LSP), the European health care investment group, today announced the nomination of three of its portfolio companies to the prestigious FierceBiotech’s 2012 Fierce 15 list of biotech companies.

LSP portfolio companies Celladon, Okairos and Prosensa have been chosen to the final 15-company list, from among more than 200 contenders from all around the globe. Martijn Kleijwegt, Managing Founding Partner of LSP is delighted: “The fact that 20% of the 2012 Fierce 15 list are LSP portfolio companies is a wonderful validation of our hard work and dedication to innovation and company building, and we are proud to be part of these exciting companies. We have played lead roles in the A rounds of both Okairos and Prosensa, and we have succeeded to attract superb syndicates for the later financing rounds. In both cases, these included highly reputable groups from the US - Versant Ventures and NEA, respectively -, which demonstrates once again that European biotechs can attract smart international money.”

This is FierceBiotech’s tenth annual Fierce 15 selection. The Fierce 15 celebrates the spirit of being “free” – championing innovation and creativity, even in the face of intense competition. A complete list of the “Fierce 15” companies can be found at www.fiercebiotech.com

About FierceBiotech
FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Sign up is free at www.fiercebiotech.com.

About LSP (www.lspvc.com)
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 650 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors.

For more information, please contact:
Martijn Kleijwegt at +31 20 664 55 00 or via yfcnzfgreqnz@yfcip.pbz « back to overview